Switch theme
Sign up to access all valuation multiples
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
2000
34
Last FY Revenue $1.3M
Last FY EBITDA -$14.3M
$870M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Lumosa Therapeutics Co achieved revenue of $1.3M and an EBITDA of -$14.3M.
Lumosa Therapeutics Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lumosa Therapeutics Co valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | $1.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $0.6M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 45% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$14.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1094% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$11.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -912% | XXX | XXX | XXX |
| Net Profit | -$10.7M | XXX | -$14.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -1085% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lumosa Therapeutics Co's stock price is TWD 162 (or $5).
Lumosa Therapeutics Co has current market cap of TWD 27.3B (or $912M), and EV of TWD 26.1B (or $870M).
See Lumosa Therapeutics Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $870M | $912M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lumosa Therapeutics Co has market cap of $912M and EV of $870M.
Lumosa Therapeutics Co's trades at 666.3x EV/Revenue multiple, and -60.9x EV/EBITDA.
Equity research analysts estimate Lumosa Therapeutics Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lumosa Therapeutics Co has a P/E ratio of -85.6x.
See valuation multiples for Lumosa Therapeutics Co and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $912M | XXX | $912M | XXX | XXX | XXX |
| EV (current) | $870M | XXX | $870M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 666.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -60.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -73.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -85.6x | XXX | -64.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -87.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLumosa Therapeutics Co's revenue per employee in the last FY averaged $38K, while opex per employee averaged $0.4M for the same period.
Lumosa Therapeutics Co's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lumosa Therapeutics Co's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lumosa Therapeutics Co and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1094% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 825% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 957% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lumosa Therapeutics Co acquired XXX companies to date.
Last acquisition by Lumosa Therapeutics Co was XXXXXXXX, XXXXX XXXXX XXXXXX . Lumosa Therapeutics Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lumosa Therapeutics Co founded? | Lumosa Therapeutics Co was founded in 2000. |
| Where is Lumosa Therapeutics Co headquartered? | Lumosa Therapeutics Co is headquartered in Taiwan. |
| How many employees does Lumosa Therapeutics Co have? | As of today, Lumosa Therapeutics Co has 34 employees. |
| Who is the CEO of Lumosa Therapeutics Co? | Lumosa Therapeutics Co's CEO is Mr. Jung-Chin Lin. |
| Is Lumosa Therapeutics Co publicy listed? | Yes, Lumosa Therapeutics Co is a public company listed on ROCO. |
| What is the stock symbol of Lumosa Therapeutics Co? | Lumosa Therapeutics Co trades under 6535 ticker. |
| When did Lumosa Therapeutics Co go public? | Lumosa Therapeutics Co went public in 2015. |
| Who are competitors of Lumosa Therapeutics Co? | Similar companies to Lumosa Therapeutics Co include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lumosa Therapeutics Co? | Lumosa Therapeutics Co's current market cap is $912M |
| Is Lumosa Therapeutics Co profitable? | Yes, Lumosa Therapeutics Co is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
